9.2
Biodisponibilité : Facteurs d’influence
La biodisponibilité correspond à l’étendue et à la vitesse auxquelles un médicament atteint la circulation systémique sous sa forme active. L’étendue…
La biodisponibilité d’un médicament peut être influencée par plusieurs facteurs.
Les propriétés physicochimiques, telles qu’une faible solubilité, peuvent diminuer l’absorption. Cette limitation peut être comblée à l’aide de formes à libération contrôlée ou à enrobage entérique.
La stabilité des médicaments dans les environnements gastriques acides a également un impact sur la biodisponibilité. Les médicaments labiles à l’acide doivent être administrés sous forme de produits tamponnés ou entérosolubles pour éviter la dégradation.
Le métabolisme de premier passage réduit considérablement les niveaux systémiques de médicaments. Par exemple, le propranolol subit un métabolisme étendu, ce qui réduit son exposition systémique. Pendant ce temps, les promédicaments comme le valacyclovir se métabolisent en acyclovir, améliorant ainsi la biodisponibilité.
La nourriture affecte également l’absorption des médicaments. Il augmente les niveaux systémiques d’isotrétinoïne mais réduit la biodisponibilité de la didanosine.
Enfin, les interactions médicamenteuses peuvent influencer l’exposition aux médicaments via le métabolisme des enzymes et des transporteurs. Par exemple, les inhibiteurs d’enzymes augmentent les niveaux systémiques en ralentissant le métabolisme, tandis que les inducteurs enzymatiques l’accélèrent, réduisant les concentrations plasmatiques de médicaments.
View the full transcript and gain access to JoVE Core videos
Q1: How do physicochemical properties affect drug bioavailability?
Physicochemical properties like poor solubility significantly decrease drug absorption and reduce bioavailability. Specialized formulations such as controlled-release or enteric-coated forms can address these limitations. For example, Neoral® microemulsion enhances cyclosporine bioavailability compared to conventional formulations by improving dissolution and absorption rates.
Q2: Why does stomach acid reduce the bioavailability of certain drugs?
Acid-labile drugs degrade in the low pH environment of the stomach, significantly reducing bioavailability. Buffered or enteric-coated formulations protect these drugs from gastric acidity, maintaining therapeutic levels. Didanosine uses these strategies to prevent degradation and ensure adequate systemic exposure for therapeutic benefit.
Q3: What is first-pass metabolism and how does it impact drug levels?
First-pass metabolism occurs when drugs are extensively metabolized in the liver during their first pass through portal circulation, significantly reducing systemic availability. Propranolol undergoes extensive first-pass metabolism, reducing its systemic exposure. Prodrugs like valacyclovir bypass this limitation by converting to active forms after absorption, enhancing bioavailability.
Q4: How do food and drug interactions influence bioavailability?
Food can enhance, reduce, or have no significant impact on drug bioavailability. Food increases isotretinoin absorption but reduces didanosine bioavailability. Drug-drug interactions also affect bioavailability through metabolizing enzymes: enzyme inhibitors like ritonavir increase systemic levels by slowing metabolism, while inducers like rifampin accelerate it, reducing plasma concentrations.
Q5: What role do transport proteins play in drug bioavailability?
Transport proteins such as P-glycoprotein significantly influence drug absorption and clearance. Drugs that inhibit or are substrates for transport proteins, like digoxin, show variable bioavailability depending on transporter activity. Understanding transporter interactions is essential for predicting drug exposure and optimizing therapeutic outcomes.
Q6: How do age and disease states affect drug bioavailability?
Aging alters bioavailability through reduced liver mass, decreased perfusion, and declining renal function, potentially increasing drug levels in geriatric patients. Renal and hepatic impairments significantly affect drug elimination: renally excreted drugs show increased bioavailability in kidney dysfunction, while hepatic impairment reduces metabolism, causing systemic drug accumulation.
Q7: What strategies address bioavailability problems in drug formulation?
Multiple strategies overcome bioavailability challenges. Controlled-release and enteric-coated formulations improve solubility and protect from gastric degradation. Prodrug design enhances absorption by converting to active forms post-absorption. Understanding bioavailability enhancement determination and conceptual approaches helps optimize formulations, dosing regimens, and therapeutic outcomes for effective patient care.